You have 9 free searches left this month | for more free features.

CAR-macrophage

Showing 1 - 25 of 1,715

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
    • (no location specified)
    Sep 19, 2023

    Advanced Solid Tumor Trial in Shanghai (B4T2-001 autologous CAR-T)

    Recruiting
    • Advanced Solid Tumor
    • B4T2-001 autologous CAR-T
    • Shanghai, China/Shanghai, China
    • +1 more
    Oct 3, 2023

    HER2-positive, Adenocarcinoma, Bile Duct Cancer Trial in United States (CT-0508)

    Recruiting
    • HER2-positive
    • +30 more
    • CT-0508
    • Duarte, California
    • +4 more
    Feb 1, 2022

    Toxicities in Children and Adults With Cancer

    Active, not recruiting
    • Macrophage Activation Syndrome
    • Primary Hemophagocytic Lymphohistiocytosis
      • Bethesda, Maryland
        National Cancer Institute (NCI)
      Sep 17, 2022

      Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer Trial in New York, Houston (AIC100 CAR T

      Recruiting
      • Anaplastic Thyroid Cancer
      • Relapsed/Refractory Poorly Differentiated Thyroid Cancer
      • AIC100 CAR T Cells
      • New York, New York
        Weill Cornell Medical College
      Feb 14, 2022

      Multiple Myeloma Trial in Shanghai (GC012F injection)

      Recruiting
      • Multiple Myeloma
      • GC012F injection
      • Shanghai, Shanghai, China
        Shanghai Changzheng Hospital
      Aug 1, 2022

      Relapsed and/or Refractory B-cell Lymphoma Trial in Stanford, Baltimore, Houston (Cyclophosphamide, Fludarabine, KITE-363)

      Recruiting
      • Relapsed and/or Refractory B-cell Lymphoma
      • Stanford, California
      • +2 more
      Aug 16, 2022

      COVID-19 Trial in Brussels (Cytokines dosage, Complement dosage)

      Completed
      • COVID-19
      • Cytokines dosage
      • Complement dosage
      • Brussels, Belgium
        CHU Brugmann
      Sep 28, 2021

      Relapsed/Refractory Large B-cell Lymphoma Trial in United States (Cyclophosphamide, Fludarabine, Lenzilumab)

      Terminated
      • Relapsed/Refractory Large B-cell Lymphoma
      • Palo Alto, California
      • +9 more
      Aug 26, 2022

      Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Trial in United States (TAK-007, Chemotherapy Agents)

      Recruiting
      • Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
      • TAK-007
      • Chemotherapy Agents
      • Birmingham, Alabama
      • +18 more
      Aug 17, 2022

      Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)

      Recruiting
      • Multiple Myeloma
      • APRIL-BAFF-Bicephali CAR-T cells
      • Xuzhou, Jiangsu, China
        Kailin Xu
      Nov 14, 2023

      Solid Tumors Trial in Kashiwa, Nishinomiya, Chuo-ku (TAK-103)

      Recruiting
      • Solid Tumors
      • TAK-103
      • Kashiwa, Chiba, Japan
      • +2 more
      Mar 10, 2022

      Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

      Not yet recruiting
      • Non-hodgkin Lymphoma
      • +9 more
      • CD79b-19 CAR T cells
      • +2 more
      • Boston, Massachusetts
        Massachusetts General Hospital
      Sep 6, 2023

      B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

      Recruiting
      • B-cell Acute Lymphoblastic Leukemia
      • +2 more
      • CD19/CD22-bispecific CAR-T cells
      • Beijing, Beijing, China
        Liang Wang
      Oct 7, 2023

      T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

      Recruiting
      • T-cell Acute Lymphoblastic Leukemia
      • +3 more
      • Universal CD7-specific CAR gene-engineered T cells
      • Beijing, Beijing, China
      • +2 more
      Aug 17, 2023

      Malignant Tumors Trial in Chengdu (EBV mRNA vaccine)

      Recruiting
      • Malignant Tumors
      • EBV mRNA vaccine
      • Chengdu, Sichuan, China
        West China Hospital, Sichuan University
      Jan 27, 2023

      Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • BTK inhibitor
      • PD-1 inhibitor
      • Shanghai, China
        Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
      May 20, 2023

      Relapsed or Refractory Large B-cell Lymphoma Trial in Nashville (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)

      Not yet recruiting
      • Relapsed or Refractory Large B-cell Lymphoma
      • Axicabtagene Ciloleucel
      • +3 more
      • (no location specified)
      Jul 13, 2022

      PET-CT Imaging in Relapsed/Refractory Acute Leukemias

      Not yet recruiting
      • B Cell
      • +2 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Aug 4, 2023

        Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

        Not yet recruiting
        • Multiple Myeloma, Refractory
        • Multiple Myeloma in Relapse
        • Autologous CAR-T cell therapy expressing the BAFF-ligand.
        • Cleveland, Ohio
          University Hospitals Seidman Cancer Center
        Jan 11, 2023

        NHL, DLBCL - Diffuse Large B Cell Lymphoma Trial in Netherlands (ARI-0001, Axi-cel)

        Recruiting
        • NHL
        • DLBCL - Diffuse Large B Cell Lymphoma
        • Amsterdam, Netherlands
        • +6 more
        Nov 30, 2022

        CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)

        Active, not recruiting
        • Central Nervous System Tumor, Pediatric
        • +8 more
        • EGFR806-specific chimeric antigen receptor (CAR) T cell
        • Seattle, Washington
          Seattle Children's Hospital
        Jan 18, 2023

        Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia Trial in United States

        Recruiting
        • Refractory Acute Myeloid Leukemia
        • +4 more
        • CD371-YSNVZ-IL18 CAR T cells
        • Basking Ridge, New Jersey
        • +6 more
        Aug 29, 2023

        Gastric Cancer, Colon Cancer, Pancreas Cancer Trial in Nanchang (CEA CAR-T cells)

        Recruiting
        • Gastric Cancer
        • +6 more
        • CEA CAR-T cells
        • Nanchang, Jiangxi, China
          The First Affiliated Hospital of Nanchang University
        Aug 23, 2023

        Leukemia, Lymphoma Trial in United States (SCRI-CAR22v2)

        Recruiting
        • Leukemia
        • Lymphoma
        • SCRI-CAR22v2
        • Los Angeles, California
        • +4 more
        Jan 18, 2023